Posts Tagged ‘Biopharma’
Ophthotech Introduces Their Antigen for WetAMD
David Guyer, CEO, discusses their novel anti-PDGF antigen for Wet AMD. Using FlowVista in combination with standard of care anti-VEGF therapy, David expands on the products successes, which have led to phase three testing and secured financing. Presenter: David Guyer, MD Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May…
Read MoreiCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema
iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which is fully enrolled in the U.S. Viewing an opportunity to better serve this population, ICO Therapeutics talks about their products that provide improved outcomes for patients not responding or only…
Read MoreEleven Biotherapeutics Gets to the Root of Ophthalmic Diseases
Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s progress over the past year. Highlighting their company’s focus on understanding the biology of key targets in ophthalmic diseases and creating protein therapeutics to treat them, Abbie details the current…
Read MoreDeveloping an Effective Dialogue with the FDA
Moderating an informative conversation surrounding FDA procedures and communication, Emmett Cunningham, Summit Chairman, draws detailed responses from Wiley Chambers and Malvina Eydelman of the FDA. Focusing the discussion around common questions on how best to interact with the FDA, both formally and informally, Emmett helps deliver the specific answers attendees at the 5th Annual Ophthalmology…
Read MoreSustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix
Amarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient outcomes, Amarpreet details the company’s proprietary technology that works across the front, back and surface of the eye. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006,…
Read MoreNeurotech Transforms the Delivery of Biologics
Ted Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics over multiple years with one simple and minimally invasive procedure. Continuing to detail the key components of their program, Ted expands on the company’s progress thus far. Presenter: Edward (Ted)…
Read MoreAMAO76 Alleviates the Pressure for Amakem Therapeutics
Jack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower intraocular pressure designated, AMAO76 rokinase inhibitor. Presenter: Jack Elands Dr. Jack Elands has been the CEO of Amakem since its inception. Before, Jack was CBO of Silicos, an informatics based…
Read MoreNPP Meets the Mark for Kala Pharmaceuticals
[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″] Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation Summit. Detailing how this technology benefits a variety of conditions, Guillaume explains how the NPP can be leveraged to treat, post cataract surgery inflammation, dry eye, plethoritis and a demonstration…
Read MoreNovaliq Clears the Obstacles in Ocular Track Delivery
Bernhard Gunther, CEO for Novaliq GmbH, introduces their approach to improving topical ocular track delivery. Detailing the challenges involved, Bernhard expands on their unique opportunity to resolve these issues by dissolving poorly soluble tracks, with low viscosity and surface tension. Presenter: Bernhard Günther Bernhard Günther joined Novaliq as CEO in January 2007. He has more…
Read MoreAerie Advances to the Next Round in Glaucoma Treatment
Vicente Anido Jr. PhD, Chairman & CEO for Aerie Pharmaceuticals, provides the attendees of the 5th Annual Ophthalmology Innovation Summit with an overview of Aeries rapid changes throughout the past year. Aerie focuses on the treatment of Glaucoma and has two major products, AR-1324 and Latanapross. Having just completed their initial Public Offering, Aerie can…
Read MoreFunding Ophthalmology Innovation: The Focus of Science and Capital
Ophthalmology is a growing, but challenging, market. Innovation is abounding in its research stages and some people in the know foresee more positive development in breakthrough technologies by 2020, while delivering drugs to the back of the eye is up front in the minds and agendas of investors and innovators. Market data and dialogue indicate…
Read MoreAll Eyes on Ophthalmic Innovation: An Interview with Bill Link
The ophthalmology drug, device and medical technology sector is poised for continued growth, as innovators and entrepreneurs unblinkingly stare down the ongoing domino effect being caused by an aging population, which begets a proliferation in eye disease incidence, which, in turn, begets an unprecedented patient base that consequently requires the types of novel ophthalmic products…
Read More